Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.
antifungal prophylaxis
chemotherapy
invasive fungal infection
isavuconazole
leukemia
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
18 05 2021
18 05 2021
Historique:
received:
05
02
2020
accepted:
30
03
2020
pubmed:
3
4
2020
medline:
3
7
2021
entrez:
3
4
2020
Statut:
ppublish
Résumé
Mold-active primary antifungal prophylaxis (PAP) is routinely recommended in neutropenic patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) undergoing remission-induction chemotherapy (RIC). Isavuconazole (ISAV) is an extended spectrum mold-active triazole and has superior tolerability and fewer significant drug-drug interactions compared with other triazoles. In our investigator-initiated, phase 2 trial, treatment-naive adult patients with AML or MDS starting RIC received ISAV per the dosing recommendations in the US label until neutrophil recovery (absolute neutrophil count [ANC] ≥ 0.5 × 109/L) and attainment of complete remission, occurrence of invasive fungal infection (IFI), or for a maximum of 12 weeks. The primary endpoint was the incidence of proven/probable IFI during ISAV PAP and up to 30 days after the last dose. Sixty-five of 75 enrolled patients received ISAV PAP (median age, 67 years, median ANC at enrollment, 0.72 × 109/L). Thirty-two patients (49%) received oral targeted leukemia treatments (venetoclax, FTL3 inhibitors). Including the 30-day follow-up period, probable/proven and possible IFIs were encountered in 4 (6%) and 8 patients (12%), respectively. ISAV trough serum concentrations were consistently > 1 µg/mL, showed low intraindividual variation, and were not significantly influenced by chemotherapy regimen. Tolerability of ISAV was excellent, with only 3 cases (5%) of mild to moderate elevations of liver function tests and no QTc prolongations. ISAV is a safe and effective alternative for PAP in patients with newly diagnosed AML/MDS undergoing RIC in the era of recently approved or emerging small-molecule antileukemia therapies. NCT03019939.
Sections du résumé
BACKGROUND
Mold-active primary antifungal prophylaxis (PAP) is routinely recommended in neutropenic patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) undergoing remission-induction chemotherapy (RIC). Isavuconazole (ISAV) is an extended spectrum mold-active triazole and has superior tolerability and fewer significant drug-drug interactions compared with other triazoles.
METHODS
In our investigator-initiated, phase 2 trial, treatment-naive adult patients with AML or MDS starting RIC received ISAV per the dosing recommendations in the US label until neutrophil recovery (absolute neutrophil count [ANC] ≥ 0.5 × 109/L) and attainment of complete remission, occurrence of invasive fungal infection (IFI), or for a maximum of 12 weeks. The primary endpoint was the incidence of proven/probable IFI during ISAV PAP and up to 30 days after the last dose.
RESULTS
Sixty-five of 75 enrolled patients received ISAV PAP (median age, 67 years, median ANC at enrollment, 0.72 × 109/L). Thirty-two patients (49%) received oral targeted leukemia treatments (venetoclax, FTL3 inhibitors). Including the 30-day follow-up period, probable/proven and possible IFIs were encountered in 4 (6%) and 8 patients (12%), respectively. ISAV trough serum concentrations were consistently > 1 µg/mL, showed low intraindividual variation, and were not significantly influenced by chemotherapy regimen. Tolerability of ISAV was excellent, with only 3 cases (5%) of mild to moderate elevations of liver function tests and no QTc prolongations.
CONCLUSIONS
ISAV is a safe and effective alternative for PAP in patients with newly diagnosed AML/MDS undergoing RIC in the era of recently approved or emerging small-molecule antileukemia therapies.
CLINICAL TRIALS REGISTRATION
NCT03019939.
Identifiants
pubmed: 32236406
pii: 5814277
doi: 10.1093/cid/ciaa358
pmc: PMC8130026
doi:
Substances chimiques
Antifungal Agents
0
Nitriles
0
Pyridines
0
Triazoles
0
isavuconazole
60UTO373KE
Banques de données
ClinicalTrials.gov
['NCT03019939']
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1755-1763Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Clin Infect Dis. 2012 Dec;55(11):1515-21
pubmed: 22955439
Curr Hematol Malig Rep. 2015 Jun;10(2):118-25
pubmed: 25939828
Curr Opin Infect Dis. 2019 Dec;32(6):538-545
pubmed: 31688198
Lancet Oncol. 2015 Dec;16(16):1691-9
pubmed: 26549589
Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S53-S70
pubmed: 29454849
J Clin Oncol. 2010 Apr 1;28(10):1766-71
pubmed: 20159819
BMC Cancer. 2019 Apr 16;19(1):358
pubmed: 30991992
Mycoses. 2018 Sep;61(9):646-649
pubmed: 29693737
Clin Infect Dis. 2010 Feb 1;50(3):405-15
pubmed: 20047485
Antimicrob Agents Chemother. 2017 Jul 25;61(8):
pubmed: 28507111
Antimicrob Agents Chemother. 2018 Dec 21;63(1):
pubmed: 30373791
Mycoses. 2019 Jan;62(1):81-86
pubmed: 30230043
Mycoses. 2020 Jan;63(1):58-64
pubmed: 31587405
Antimicrob Agents Chemother. 2014 May;58(5):2775-80
pubmed: 24590477
Antimicrob Agents Chemother. 2017 Nov 22;61(12):
pubmed: 28971866
Clin Ther. 2017 Feb;39(2):359-367
pubmed: 28161120
Diagn Microbiol Infect Dis. 2013 Feb;75(2):144-9
pubmed: 23142166
Clin Infect Dis. 2018 Oct 30;67(10):1610-1613
pubmed: 29771293
N Engl J Med. 2007 Jan 25;356(4):348-59
pubmed: 17251531
Future Microbiol. 2015;10(5):693-708
pubmed: 26000646
J Clin Oncol. 2003 Dec 15;21(24):4642-9
pubmed: 14673054
Mycoses. 2011 Jan;54 Suppl 1:32-8
pubmed: 21126270
J Antimicrob Chemother. 2018 Mar 1;73(3):757-763
pubmed: 29194488
Blood. 2019 Jan 3;133(1):7-17
pubmed: 30361262
Front Pharmacol. 2019 Jun 21;10:697
pubmed: 31293422
Blood. 2010 Dec 23;116(26):5818-23; quiz 6153
pubmed: 20923968
Ther Adv Hematol. 2019 Feb 15;10:2040620719827310
pubmed: 30800259
Lancet. 2016 Feb 20;387(10020):760-9
pubmed: 26684607
Curr Opin Infect Dis. 2011 Aug;24(4):323-32
pubmed: 21666457
Clin Infect Dis. 2008 Jun 15;46(12):1813-21
pubmed: 18462102
N Engl J Med. 2017 Aug 3;377(5):454-464
pubmed: 28644114
Clin Infect Dis. 2019 Oct 15;69(9):1624-1627
pubmed: 30861066
Blood. 2015 Dec 24;126(26):2790-7
pubmed: 26504183
Clin Infect Dis. 2018 Oct 30;67(10):1621-1630
pubmed: 29860307
J Antimicrob Chemother. 2017 Feb;72(2):462-466
pubmed: 27798213